The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...
European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...
Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...
The US Food and Drug Administration has approved the supplemental biologics licence application (sBLA) of Eisai and Biogen's ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
Seeking Alpha on MSN4d
Biogen, Eisai Alzheimer’s drug review delayed in EUBiogen (BIIB) stock in focus as company and partner Eisai (ESALF) face delay in the EU launch of Alzheimer's drug lecanemab.
Biogen and Eisai said they believe that EC's requests can be addressed with existing information, and that no new safety signals have been identified for Leqembi. The U.S. Food and Drug Administration ...
GlobalData on MSN10d
MSD and Eisai’s LEAP gastroesophageal cancer trial sees mixed successMSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
Eisai and Biogen update on lecanemab's EU regulatory review for early Alzheimer’s disease treatment following positive CHMP opinion. Eisai Co., Ltd. and Biogen Inc. have provided an update on ...
Biogen (BIIB) and Eisai announced an update on the ongoing regulatory review of the Marketing Authorization Application for lecanemab as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback